Work

Talimogene Laherparepvec treatment for mucosal melanoma with metastatic lymph node metastasis: case report

Year: 2025

Type: article

Abstract: Mucosal melanoma is a rare and aggressive subtype of melanoma, accounting for approximately 1% of all melanoma cases. Of those, only 4% occur primarily in the vagina. Talimogene Laherparepvec (T-VEC) is a biopharmaceutical medication that is used to treat unresectable malignant melanoma. However, the clinical trials for this treatment option excluded patients with mucosal melanomas. Here we report a case of an 85-year-old female with vaginal melanoma with regional lymph node metastasis that had complete durable response to combined T-VEC and immune checkpoint inhibition treatment. This is, to our best knowledge, the first reported case of T-VEC treatment for vaginal melanoma. It supports findings from case reports demonstrating good response to T-VEC in mucosal melanomas of the urethra, maxillary sinus, and the soft and hard palate. Prospective studies assessing the efficacy of T-VEC in treating mucosal melanoma are needed to confirm these findings.

Source: Frontiers in Oncology

DOI: 10.3389/fonc.2025.1647603

Authors: Arnar B. Ingason, Venkatesa P. Muruganandam, Ikechukwu Chidobem, Jessica Cintolo-Gonzalez, Hibba tul Rehman

Institutions: University of Vermont, University of Vermont Medical Center

Language: English

Topic: Cutaneous Melanoma Detection and Management

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,801